Extended Data Table 1 |.
Patient number | Sample Information | IgH Repertoire Assessment | Tumor Clone | |||||
---|---|---|---|---|---|---|---|---|
Sample type | Infusion1 | Cell Equivalent2 | Productive Total3 | Productive Uniques4 | CLL clonotype sequence | Counts (reads) | Frequency5 | |
01 | PB | Baseline | 158,730 | 408,579 | 48 | CARDCSSSNCYEKG | 407,592 | 99.76% |
Mo 6 | 79,365 | 285,305 | 7,362 | ND | 0 | 0.00% | ||
Yr 1 | N/A | 41 | 12 | ND | 0 | 0.00% | ||
Yr 3 | 298,667 | 91 | 6 | ND | 0 | 0.00% | ||
Yr 3.5 | 350,171 | 123 | 8 | ND | 0 | 0.00% | ||
Yr 4 | 277,943 | 157 | 10 | ND | 0 | 0.00% | ||
Yr 4.5 | 238,933 | 107 | 12 | ND | 0 | 0.00% | ||
Yr 5 | 270,629 | 94 | 8 | ND | 0 | 0.00% | ||
Yr 5.5 | 291,810 | 75 | 12 | ND | 0 | 0.00% | ||
Yr 8 | 395,249 | 339 | 12 | ND | 0 | 0.00% | ||
BM | Mo 1 | 408,838 | 29 | 3 | ND | 0 | 0.00% | |
Mo 6 | 158,730 | 202,535 | 4,451 | ND | 0 | 0.00% | ||
Yr 1 | NA | 18,506 | 231 | ND | 0 | 0.00% | ||
Yr 2 | 279,924 | 88 | 2 | ND | 0 | 0.00% | ||
02 | Baseline | 61,270 | 1,385,340 | 4,544 | CTTQTRTTIVFLDYYYYYMDVWGKG | 1,231,018 | 88.86% | |
Mo 6 | N/A | 25,041 | 38 | ND | 0 | 0.00% | ||
Mo 32 | 317,714 | 88 | 8 | ND | 0 | 0.00% | ||
Yr 3 | 346,057 | 160 | 8 | ND | 0 | 0.00% | ||
Yr 4 | 308,419 | 212 | 10 | ND | 0 | 0.00% | ||
Yr 4.5 | 257,067 | 52 | 8 | ND | 0 | 0.00% | ||
Yr 4.7 | 258,895 | - | - | ND | 0 | N/A | ||
Yr 5 | 233,143 | 74 | 6 | ND | 0 | 0.00% | ||
Yr 6 | 246,705 | - | - | ND | 0 | N/A | ||
BM | Yr 1 | N/A | 5 | 2 | ND | 0 | 0.00% | |
Yr 2 | 222,019 | 601 | 25 | ND | 0 | 0.00% |
Day/month/year relative to infusion date;
Cell equivalent sequenced, assuming that each diploid human cell contains 6.3 pg genomic DNA;
IgH rearrangements potentially encoding a functional IgH protein;
Number of unique productively rearranged IgH alleles;
The frequency of the leukemic clone as a proportion of all productively rearranged IgH alleleles;
N/A, Not available; ND, not detectable